Boosting RSV immunity: More options available soon?

+Practice

In print

Vaccines

Boosting RSV immunity: More options available soon?

5 June 2024

Mary Nowlan

Wednesday 5 June 2024, 12:20 AM

Infants can obtain passive immunity to respiratory syncytial virus via maternal vaccination and/or monoclonal antibody prophylaxis [Image: Han Myo Htwe on Unsplash]

This article provides an update on respiratory syncytial virus vaccines and monoclonal antibodies

Key points, Severe respiratory syncytial virus infections in the youngest children and older adults require hospital care and are a major cause of deaths. Repea, Pract Green w Pale Yellow

Infectious Disease

References

1. Prasad N, Newbern EC, Trenholme AA, et al. The health and economic burden of respiratory syncytial virus associated hospitalizations in adults. PLoS One 2020;15(6):e0234235.

2. Eiland LS. Respiratory syncytial virus: diagnosis, treatment and prevention. J Pediatr Pharmacol Ther 2009;14(2):75–85.

3. Shi T, Vennard S, Mahdy S, Nair H. Risk factors for poor outcome or death in young children with respiratory syncytial virus-associated acute lower respiratory tract infection: A systematic review and meta-analysis. J Infect Dis 2022;226(Suppl 1):S10–16.

4. Brenes-Chacon H, Garcia-Maurino C, Moore-Clingenpeel M, et al. Age-dependent interactions among clinical characteristics, viral loads and disease severity in young children with respiratory syncytial virus infection. Pediatr Infect Dis J 2021;40(2):116–22.

5. Prasad N, Newbern EC, Trenholme AA, et al. Respiratory syncytial virus hospitalisations among young children: a data linkage study. Epidemiol Infect 2019;147:e246.

6. Ison MG, Papi A, Athan E, et al. Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clin Infect Dis 2024; 22 January online.

7. Walsh EE, Pérez Marc G, Zareba AM, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med 2023;388(16):1465–77.

8. Pfizer. Pfizer announces positive top-line data for full season two efficacy of Abrysvo® for RSV in older adults [press release]. 29 February 2024.

9. Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med 2023;388(16):1451–64.

10. Pfizer. Respiratory syncytial virus stabilized bivalent prefusion F subunit vaccine (RSVpreF/Abrysvo). Briefing document for Vaccine and Related Biological Products Advisory Committee Meeting, 18 May 2023.

11. Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med 2022;386(9):837–46.

How to Treat

Paediatric eczema

Specialist GP Nikki Vadgama provides some tips to make your next paediatric eczema consult easier. She includes a review of new guidelines, resources, websites and medications for paediatric eczema management

Wednesday 14 August 2024, 12:45 AM